Inflammatix, a leader in host-response diagnostics, today announced that its TriVerity™ Test has been granted New Technology Add-On Payment (NTAP) reimbursement by the Centers for Medicare & Medicaid Services (CMS) for fiscal year 2026. The NTAP decision, driven by TriVerity's novelseverity score-enabled by its FDA Breakthrough Device designation-recognizes the test's unique clinical utility in helping emergency physicians rapidly and accurately triage patients with suspected infection or sepsis.
https://mma.prnewswire.com/media/2147953/Inflammatix_Logo.jpg
Unlike conventional diagnostics that focus solely on identifying pathogens,TriVerity deliversthree integrated host-response scores-bacterial infection, viral infection, and illnessseverity-from a single blood draw within ~30 minutes.The test's breakthrough advantage lies in how these scores work together to guide not just diagnosis, butdisposition-supporting clinicians in determiningwhat kind of infection a patient has, how sick they are, and what level of care they needright now.
“TriVerity gives clinicians a complete picture in real time,” said Tim Sweeney, M.D., Ph.D., CEO and co-founder of Inflammatix. “The severity score is critical-it identifies patients at risk for poor outcomes like ICU admission or death-but it's the combination with infection type that makes it transformational. When a physician knows bothwhatthey're treating andhow urgentlythe patient needs care, they can make faster, more accurate decisions that improve outcomes and resource use.”
The severity score-central to the NTAP approval-is the first of its kind to translate host-response biomarkers into a quantitative risk score that predicts clinical deterioration. This supports earlier identification of high-risk patients, more confident discharge of low-acuity cases, and better alignment of patients to beds, therapies, and teams.
With NTAP reimbursement, hospitals using TriVerity in eligible inpatient cases will receive additional payment on top of the standard DRG rate-removing a key barrier to adoption of cutting-edge diagnostics that improve emergency care.
About InflammatixInflammatix is a molecular diagnostics company transforming the way acute infection and sepsis are diagnosed and managed. Its flagship product, TriVerity™, leverages the immune system's response to deliver three host-response scores-bacterial infection, viral infection, and severity. The company is backed byleading investors-including Khosla Ventures, Northpond Ventures, Think.Health Ventures, D1 Capital, Iberis Capital, Vesalius BioCapital, and the Stanford-StartX Fund-Inflammatix is setting a new standard for acute diagnostics. Learn more atwww.inflammatix.comor follow us on LinkedIn and X (formerly Twitter) at @Inflammatix_Inc.
Inflammatix's programs have been supported in part by funding from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; and the Biomedical Advanced Research and Development Authority (BARDA), under contract numbers 75A50119C00034, 75A50119C00044, and 75A50122C00069.
https://c212.net/c/img/favicon.png?sn=SF43446&sd=2025-08-04
View original content to download multimedia:https://www.prnewswire.com/news-releases/inflammatixs-triverity-test-secures-ntap-reimbursement-from-cms-for-first-in-class-severity-score-working-in-concert-with-bacterial-and-viral-insights-302520678.html
SOURCE Inflammatix
https://rt.newswire.ca/rt.gif?NewsItemId=SF43446&Transmission_Id=202508040805PR_NEWS_USPR_____SF43446&DateId=20250804